Kaplan-Meier estimates across dose groups of time to progression (all patients), time to progression (responders), duration of response, and time to next anti-FL therapy. Based on Kaplan-Meier estimates, at a median/maximum follow-up of 9.2/38.6 months, the median TTP for all patients was 8.8 months (95% CI, 5.4-20.0 months), the median TTP for responders was 32.6 months (95% CI, 22.4-38.6 months), and the median duration of response was 29.9 months (95% CI, 19.7-36.1 months). The median time to next anti-FL therapy was not reached during the study period, and data were not collected after month 12. Given for a time point where estimates could be calculated, the proportion of patients who had time to next FL therapy more than 8.5 months was 80% (67%; 100%). All indicates 40 patients.